ABSTRACT
In the past 15 years, the number of clinical applications of intravenous immunoglobulin (IVIG) has grown far beyond expectations. Originally intended to supply antibodies to patients with primary immunodeficiency disorders who are antibody-deficient, IVIGs have been found to benefit many other types of patients. This is because IVIG contains thousands of different antibodies, each of which may have the potential to produce a clinical effect.
